Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy

Tschernatsch, Marlene; Singh, Pratibha; Groß, Oliver; Gerriets, Tibo; Kneifel, N.; Probst, C; Malas, Stavros; Kaps, Manfred; Blaes, Franz

doi:10.1016/j.jneuroim.2010.07.005

Cited by 47 publications

(48 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies on antibodies in lung cancer patients identi fi ed anti-Hu (Graus et al 1985 ;Monstad et al 2004 ) , anti-Ri (Pittock et al 2003 ;Knudsen et al 2006 ) , anti-CV2 (Yu et al 2001 ;Monstad et al 2008 ) , and antiamphiphysin (Antoine et al 1999 ;Pittock et al 2005 ) . Among other antibodies detected in lung cancer, anti-SOX (Tschernatsch et al 2010 ) , anti-VGCC (anti-voltage gated calcium channels) (Monstad et al 2004 ) , anti-AMPA (Lai et al 2009 ) , anti-GABA (Lancaster et al 2010 ) , and anti-aquaporin (Pittock and Lennon 2008 ) were observed. Anti-aquaporin antibodies are currently used for the diagnosis of neuromyelitis optica and their paraneoplastic context has not been widely studied.…”

Section: Discussionmentioning

confidence: 98%

Neurological Paraneoplastic Syndromes in Lung Cancer Patients

Stefens-Stawna

Piorunek

Gabryel-Batura

et al. 2012

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Lung cancer is recognized among the most frequent causes of paraneoplastic neurological syndromes (PNS). Neurological syndromes in subjects with systemic malignancy remain a clinical and diagnostic challenge. The aim of the study was to evaluate the frequency of NPS, their clinical manifestation and association with onconeural antibodies in patients with lung cancer. Fifty patients hospitalized with the diagnosis of PNS participated in the study. Neurological evaluation consisted of the Rankin scale (mRS), the Barthel index (BI), and testing for the presence of onconeural antibodies by means of indirect immunofluorescence, as screening, and Western blotting as confirmation. The majority of lung cancer patients (64%) aged 62 ± 10 had NPS symptoms. Their neurological condition and daily living activities were reasonable: mRS (1.0; 0.0-4.0) and BI (100; 7.4-100) scores. Classical PNS were found in 30% of cases and included sensory neuropathy (16%), paraneoplastic cerebellar degeneration (12%) as the most frequent symptoms. Autoimmune reaction was observed in 42% of lung cancer patients and in 20% was represented by well-characterized onconeural antibodies. Anti-Hu antibody was identified as the most frequent. In conclusion, PNS signs in lung cancer patients have both classical and non-classical features. In the course of SCLC only well-characterized onconeural antibodies were identified. The presence of well-characterized onconeural antibodies is strongly associated with classical features of PNS.

show abstract

Section: Discussionmentioning

confidence: 98%

Neurological Paraneoplastic Syndromes in Lung Cancer Patients

Stefens-Stawna

Piorunek

Gabryel-Batura

et al. 2012

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…Den diagnostiske verdien av anti-SOX-1-anistoffer for å identifisere paraneoplastiske og ikke-paraneoplastiske lidelser er ikke fullt kartlagt (19).…”

Section: Diskusjonunclassified

En mann i 50-årene med svimmelhet, dobbeltsyn og gangvansker

Bajwa¹,

Nilsen²,

Erichsen³

et al. 2018

Tidsskriftet

View full text Add to dashboard Cite

“…After resection, chemotherapy, and radiation treatments, she had near resolution of neurologic symptoms and improvement in electrophysiology measures; anti-CRMP titer was no longer detectable. A study of 32 patients with probable paraneoplastic neuropathy compared them to patients with inflammatory neuropathy, idiopathic neuropathy, and healthy controls [28]. Anti-SOX1 (sarcosine oxidase 1) antibody was found in 16% of the paraneoplastic neuropathy patients and 18% of idiopathic neuropathy patients, but none in the inflammatory neuropathy patients or healthy controls.…”

Section: Paraneoplastic Antibodiesmentioning

confidence: 99%

Advances in the Laboratory Evaluation of Peripheral Neuropathies

Huan

Bromberg

2011

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Peripheral neuropathy is a common clinical problem in neurology and laboratory testing is an integral part of diagnosis. In the past few years, practice parameters have been published to establish an evidence-based guide to neuropathy testing. There are many tests that are common and accepted in practice, but there is no clear mandate on which tests are necessary. This article reviews recent practice parameter publications as well as other updates in laboratory testing for peripheral neuropathy, including the roles of lipid profile, genetic testing, antibody titers, and B(12) testing in a specific dopamine-treated Parkinson's patients. These can serve as recommendations to help guide laboratory testing.

show abstract

Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy

Cited by 47 publications

References 14 publications

Neurological Paraneoplastic Syndromes in Lung Cancer Patients

Neurological Paraneoplastic Syndromes in Lung Cancer Patients

En mann i 50-årene med svimmelhet, dobbeltsyn og gangvansker

Advances in the Laboratory Evaluation of Peripheral Neuropathies

Contact Info

Product

Resources

About